2026-10-13T18:00:43Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33956680 2026-09-21T17:36:49Z category_12 category_15 category_21 category_64 category_122 category_132 portal_5 item_type_3 month_year_09_2026

<p>Research Data.</p> Ngozi Murphy-Okpala (18840734) Charles Nwafor (3502961) Chinwe Eze (18840722) Martin Njoku (3502994) Okechukwu Ezeakile (20766212) Anthony Meka (3502979) Ngozi Ekeke (3502973) Francis Iyama (25084651) Daniel Egbule (17804357) Chukwuma Anyaike (3611552) Obioma Chijioke-Akaniro (20547897) Joseph Chukwu (3502964) Beatrice Kirubi (757884) Jacob Creswell (471745) Justus Uchenna Onu (20868850) Cell Biology Neuroscience Biotechnology Cancer Mental Health Infectious Diseases clinical trial number 57 ), indicating reducing depressive symptoms depressive symptoms completed specialist health workers higher scores seen standard tb care th </ sup depression treatment led two control sites significant depressive symptoms depression symptom scores depression care compared div >< p completing tb treatment depression treatment delivered subjects across intervals depressive symptoms delivered treatment control arms tb treatment two groups treat analyses study determined study arms social support similar way significantly associated significant differences resource setting referred patients persons treated per protocol marked decrease intervention sites findings indicated different setting decreased significantly anova design achieving cure achieved cure 9 scores 9 ). 32 ). 001 ). <div><p>This study determined the effectiveness of integrated TB and depression care compared to standard TB care in reducing depressive symptoms over time in persons treated for TB. This was a quasi-experimental, non-randomized controlled trial involving all TB cases with significant depressive symptoms (PHQ score ≥ 5) in ten already existing sites (i.e., eight intervention sites and two control sites) in Nigeria. At the intervention sites, non-specialist health workers (NSHWs) delivered treatment for both TB and depression while the NSHWs in the control sites delivered TB treatment and then referred patients with depression to a specialist in a different setting for treatment. Changes in depression symptom scores were measured at baseline, 2^nd, 8^th and 24^th weeks using Patient Health Questionnaire (PHQ-9). Mixed-ANOVA design was used to determine changes in PHQ-9 scores between-subjects and within-subjects across intervals of follow-up using both the per protocol and intent-to-treat analyses while controlling for covariates such as age, social support, sex, education. There were no significant differences in the PHQ-scores between the two groups (F = 0.95, p = 0.32). In addition, across the intervals of follow-up, PHQ-scores (i.e., depressive symptom scores) decreased significantly with time in both the intervention and control arms (p < 0.001). Furthermore, the interaction between the study arms and time was not significant (F = 0.66, p = 0.57), indicating that the groups were changing over time in a similar way. Participants with marked decrease in depressive symptoms completed their TB treatment and achieved cure when compared to the higher scores seen in those who dropped out or died or were transferred (F = 25.78, p < 0.001). The findings indicated that TB and depression treatment delivered by NSHWs significantly reduced depressive symptoms across intervals of follow-up. In addition, relief from depressive symptoms was significantly associated with completing TB treatment and achieving cure. Clinical Trial Number: PACTR202501828312848.</p></div> 2026-09-21T17:36:46Z Dataset Dataset 10.1371/journal.pmen.0000636.s001 https://figshare.com/articles/dataset/_p_Research_Data_p_/33956680 CC BY 4.0